TY - JOUR
T1 - Overview of thermal ablation devices for treating precancerous cervical lesions in low-resource settings
AU - Boles, Taylor
AU - Salcedo, Mila Pontremoli
AU - Lorenzoni, Cesaltina
AU - Osman, Nafissa
AU - Baker, Ellen
AU - Schmeler, Kathleen
AU - Carns, Jennifer
N1 - Funding Information:
Funding: This research was supported in part by the National Academy of Sciences and United States Agency for International Development (Partnerships for Enhanced Engagement in Research, Cooperative Agreement AID-OAA-A-11-00012). The content is solely the responsibility of the authors and does not necessarily reflect the official views of the acknowledged funding agencies.
Publisher Copyright:
© 2022 THE AUTHOR(S)JoGH © 2022 ISoGH
PY - 2022
Y1 - 2022
N2 - In 2020, there were an estimated 604 000 cases and 341 000 deaths from cervical cancer [1], with 91% of these deaths occurring in low and middle-income countries (LMICs) [2]. While screening programs have led to a dramatic reduction in cervical cancer rates in high-income countries, their implementation in LMICs has faced many challenges [3]. Screen-and-treat programs, where screening is achieved with human papillomavirus (HPV) testing and/or visual inspection with acetic acid (VIA), have limited impact when feasible treatment options for precancerous cervical lesions are not available. Cryotherapy has historically been recommended as an ablative treatment, but implementation challenges related to obtaining and transporting the necessary refrigerant gas have limited its use in many low-resource settings [4,5]. Similar to cryotherapy, thermal ablation does not require anaesthesia and can be provided by a variety of health care providers [4]. Thermal ablation devices are simple to use, lightweight, portable, and easier to implement than cryotherapy in many settings, while the necessary treatment time for thermal ablation is much shorter than for cryotherapy [4,6]. When thermal ablation is used to treat precancerous cervical lesions at 100-120°C for 20-45 seconds, the depth of necrosis is sufficient, with cure rates comparable to those achieved with cryotherapy [6].
AB - In 2020, there were an estimated 604 000 cases and 341 000 deaths from cervical cancer [1], with 91% of these deaths occurring in low and middle-income countries (LMICs) [2]. While screening programs have led to a dramatic reduction in cervical cancer rates in high-income countries, their implementation in LMICs has faced many challenges [3]. Screen-and-treat programs, where screening is achieved with human papillomavirus (HPV) testing and/or visual inspection with acetic acid (VIA), have limited impact when feasible treatment options for precancerous cervical lesions are not available. Cryotherapy has historically been recommended as an ablative treatment, but implementation challenges related to obtaining and transporting the necessary refrigerant gas have limited its use in many low-resource settings [4,5]. Similar to cryotherapy, thermal ablation does not require anaesthesia and can be provided by a variety of health care providers [4]. Thermal ablation devices are simple to use, lightweight, portable, and easier to implement than cryotherapy in many settings, while the necessary treatment time for thermal ablation is much shorter than for cryotherapy [4,6]. When thermal ablation is used to treat precancerous cervical lesions at 100-120°C for 20-45 seconds, the depth of necrosis is sufficient, with cure rates comparable to those achieved with cryotherapy [6].
UR - http://www.scopus.com/inward/record.url?scp=85145044097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145044097&partnerID=8YFLogxK
U2 - 10.7189/JOGH.12.03089
DO - 10.7189/JOGH.12.03089
M3 - Article
C2 - 36579405
AN - SCOPUS:85145044097
SN - 2047-2978
VL - 12
JO - Journal of global health
JF - Journal of global health
M1 - 03089
ER -